[{"address1": "3891 Ranchero Drive", "address2": "Suite 150", "city": "Ann Arbor", "state": "MI", "zip": "48108", "country": "United States", "phone": "734 887 3903", "website": "https://www.esperion.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.", "fullTimeEmployees": 240, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sheldon L. Koenig", "age": 57, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1278804, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 5, "compensationRisk": 6, "shareHolderRightsRisk": 9, "overallRisk": 6, "governanceEpochDate": 1726617600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.74, "open": 1.77, "dayLow": 1.73, "dayHigh": 1.85, "regularMarketPreviousClose": 1.74, "regularMarketOpen": 1.77, "regularMarketDayLow": 1.73, "regularMarketDayHigh": 1.85, "beta": 1.001, "forwardPE": 7.0, "volume": 3304356, "regularMarketVolume": 3304356, "averageVolume": 5680300, "averageVolume10days": 2976890, "averageDailyVolume10Day": 2976890, "bid": 1.7, "ask": 1.75, "bidSize": 900, "askSize": 2400, "marketCap": 343393728, "fiftyTwoWeekLow": 0.7, "fiftyTwoWeekHigh": 3.4, "priceToSalesTrailing12Months": 1.236172, "fiftyDayAverage": 2.0194, "twoHundredDayAverage": 2.2631, "currency": "USD", "enterpriseValue": 423224224, "profitMargins": -0.35458001, "floatShares": 194821688, "sharesOutstanding": 196224992, "sharesShort": 40438871, "sharesShortPriorMonth": 38135175, "sharesShortPreviousMonthDate": 1722384000, "dateShortInterest": 1724976000, "sharesPercentSharesOut": 0.2061, "heldPercentInsiders": 0.00501, "heldPercentInstitutions": 0.70524, "shortRatio": 9.25, "shortPercentOfFloat": 0.2066, "impliedSharesOutstanding": 196224992, "bookValue": -1.769, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -98497000, "trailingEps": -0.85, "forwardEps": 0.25, "pegRatio": -0.58, "enterpriseToRevenue": 1.524, "enterpriseToEbitda": 84.814, "52WeekChange": 0.7676767, "SandP52WeekChange": 0.32258344, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ESPR", "underlyingSymbol": "ESPR", "shortName": "Esperion Therapeutics, Inc.", "longName": "Esperion Therapeutics, Inc.", "firstTradeDateEpochUtc": 1372253400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "00314c6d-38c1-3c8e-a318-bd51d9ba1c8c", "messageBoardId": "finmb_28236", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.75, "targetHighPrice": 16.0, "targetLowPrice": 2.55, "targetMeanPrice": 7.59, "targetMedianPrice": 6.5, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 189304000, "totalCashPerShare": 0.965, "ebitda": 4990000, "totalDebt": 269135008, "quickRatio": 1.424, "currentRatio": 1.968, "totalRevenue": 277788000, "revenuePerShare": 1.907, "returnOnAssets": 0.01054, "freeCashflow": 6908125, "operatingCashflow": -9758000, "revenueGrowth": 1.863, "grossMargins": 0.6112, "ebitdaMargins": 0.01796, "operatingMargins": 0.034930002, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-20"}]